A citation-based method for searching scientific literature

Emmanuel S Antonarakis. N Engl J Med 2018
Times Cited: 43







List of co-cited articles
374 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, Pankaj Vats, Melissa A Reimers, Xuhong Cao, Yu Ning, Lisha Wang, Lakshmi P Kunju, Navonil de Sarkar,[...]. Cell 2018
272
86

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
265
51

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
41

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Karim Boudadi, Daniel L Suzman, Valsamo Anagnostou, Wei Fu, Brandon Luber, Hao Wang, Noushin Niknafs, James R White, John L Silberstein, Rana Sullivan,[...]. Oncotarget 2018
98
39

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L Maughan, Roberto Pili, Nabil Adra, Cora N Sternberg,[...]. JCO Precis Oncol 2020
76
39

Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
Emmanuel S Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, Harsimar Kaur, Eugene Shenderov, Drew M Pardoll, Tamara L Lotan. Eur Urol 2019
93
37

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
34

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Tomasz M Beer, Eugene D Kwon, Charles G Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski,[...]. J Clin Oncol 2017
405
34

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi,[...]. Lancet Oncol 2014
937
32

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
244
32

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015
30

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
Colin C Pritchard, Joaquin Mateo, Michael F Walsh, Navonil De Sarkar, Wassim Abida, Himisha Beltran, Andrea Garofalo, Roman Gulati, Suzanne Carreira, Rosalind Eeles,[...]. N Engl J Med 2016
819
30

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
A R Hansen, C Massard, P A Ott, N B Haas, J S Lopez, S Ejadi, J M Wallmark, B Keam, J-P Delord, R Aggarwal,[...]. Ann Oncol 2018
179
30

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.
Ethan S Sokol, Dean Pavlick, Garrett M Frampton, Jeffrey S Ross, Vincent A Miller, Siraj M Ali, Tamara L Lotan, Drew M Pardoll, Jon H Chung, Emmanuel S Antonarakis. Oncologist 2019
25
52

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Melissa A Reimers, Steven M Yip, Li Zhang, Marcin Cieslik, Mallika Dhawan, Bruce Montgomery, Alexander W Wyatt, Kim N Chi, Eric J Small, Arul M Chinnaiyan,[...]. Eur Urol 2020
43
30


Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
25

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Wassim Abida, David Campbell, Akash Patnaik, Jeremy D Shapiro, Brieuc Sautois, Nicholas J Vogelzang, Eric G Voog, Alan H Bryce, Ray McDermott, Francesco Ricci,[...]. Clin Cancer Res 2020
156
25

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
23

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
601
23

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.
Michael C Haffner, Gunes Guner, Diana Taheri, George J Netto, Doreen N Palsgrove, Qizhi Zheng, Liana Benevides Guedes, Kunhwa Kim, Harrison Tsai, David M Esopi,[...]. Am J Pathol 2018
84
20

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo, Nuria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,[...]. Lancet Oncol 2020
257
20

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
David A Quigley, Ha X Dang, Shuang G Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J Alumkal, Adam Foye, Vishal Kothari, Marc D Perry, Adina M Bailey,[...]. Cell 2018
257
18

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane,[...]. J Clin Invest 2018
94
18

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
18

Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Srinivas R Viswanathan, Gavin Ha, Andreas M Hoff, Jeremiah A Wala, Jian Carrot-Zhang, Christopher W Whelan, Nicholas J Haradhvala, Samuel S Freeman, Sarah C Reed, Justin Rhoades,[...]. Cell 2018
162
18

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ilirjana Bajrami, Jessica R Frankum, Asha Konde, Rowan E Miller, Farah L Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper,[...]. Cancer Res 2014
213
18

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Julie N Graff, Joshi J Alumkal, Charles G Drake, George V Thomas, William L Redmond, Mohammad Farhad, Jeremy P Cetnar, Frederick S Ey, Raymond C Bergan, Rachel Slottke,[...]. Oncotarget 2016
239
16

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Colin C Pritchard, Colm Morrissey, Akash Kumar, Xiaotun Zhang, Christina Smith, Ilsa Coleman, Stephen J Salipante, Jennifer Milbank, Ming Yu, William M Grady,[...]. Nat Commun 2014
175
16

Increased survival with enzalutamide in prostate cancer after chemotherapy.
Howard I Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N Sternberg, Kurt Miller, Ronald de Wit, Peter Mulders, Kim N Chi, Neal D Shore,[...]. N Engl J Med 2012
16


CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Sara J Dubbury, Paul L Boutz, Phillip A Sharp. Nature 2018
102
16

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Dalibor Blazek, Jiri Kohoutek, Koen Bartholomeeusen, Eric Johansen, Petra Hulinkova, Zeping Luo, Peter Cimermancic, Jernej Ule, B Matija Peterlin. Genes Dev 2011
284
16

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Fatima Karzai, David VanderWeele, Ravi A Madan, Helen Owens, Lisa M Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L Beshiri,[...]. J Immunother Cancer 2018
135
16

CDK12 inactivation across solid tumors: an actionable genetic subtype.
Catherine H Marshall, Eddie L Imada, Zhuojun Tang, Luigi Marchionni, Emmanuel S Antonarakis. Oncoscience 2019
12
58

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Catherine H Marshall, Alexandra O Sokolova, Andrea L McNatty, Heather H Cheng, Mario A Eisenberger, Alan H Bryce, Michael T Schweizer, Emmanuel S Antonarakis. Eur Urol 2019
71
16

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Victor Quereda, Simon Bayle, Francesca Vena, Sylvia M Frydman, Andrii Monastyrskyi, William R Roush, Derek R Duckett. Cancer Cell 2019
90
16

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L Silberstein, Danilo Piana, Zhao Lai, Yidong Chen,[...]. Eur Urol 2018
108
13

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
Jennifer L Bishop, Alexander Sio, Arkhjamil Angeles, Morgan E Roberts, Arun A Azad, Kim N Chi, Amina Zoubeidi. Oncotarget 2015
182
13

PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Pedro Isaacsson Velho, Emmanuel S Antonarakis. Expert Rev Clin Pharmacol 2018
53
13

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.
Jennifer A Hempelmann, Christina M Lockwood, Eric Q Konnick, Michael T Schweizer, Emmanuel S Antonarakis, Tamara L Lotan, Bruce Montgomery, Peter S Nelson, Nola Klemfuss, Stephen J Salipante,[...]. J Immunother Cancer 2018
60
13

MSH2 Loss in Primary Prostate Cancer.
Liana B Guedes, Emmanuel S Antonarakis, Michael T Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie Glavaris, Jessica Hicks, Mario A Eisenberger, Angelo M De Marzo,[...]. Clin Cancer Res 2017
91
13

Alpha emitter radium-223 and survival in metastatic prostate cancer.
C Parker, S Nilsson, D Heinrich, S I Helle, J M O'Sullivan, S D Fosså, A Chodacki, P Wiechno, J Logue, M Seke,[...]. N Engl J Med 2013
13

The long tail of oncogenic drivers in prostate cancer.
Joshua Armenia, Stephanie A M Wankowicz, David Liu, Jianjiong Gao, Ritika Kundra, Ed Reznik, Walid K Chatila, Debyani Chakravarty, G Celine Han, Ilsa Coleman,[...]. Nat Genet 2018
397
13

Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Tatiana Popova, Elodie Manié, Valentina Boeva, Aude Battistella, Oumou Goundiam, Nicholas K Smith, Christopher R Mueller, Virginie Raynal, Odette Mariani, Xavier Sastre-Garau,[...]. Cancer Res 2016
64
13

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera,[...]. J Clin Oncol 2019
153
13

Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Bastien Nguyen, Jose Mauricio Mota, Subhiksha Nandakumar, Konrad H Stopsack, Emily Weg, Dana Rathkopf, Michael J Morris, Howard I Scher, Philip W Kantoff, Anuradha Gopalan,[...]. Eur Urol 2020
40
15

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Michael T Schweizer, Gavin Ha, Roman Gulati, Landon C Brown, Rana R McKay, Tanya Dorff, Anna C H Hoge, Jonathan Reichel, Pankaj Vats, Deepak Kilari,[...]. JCO Precis Oncol 2020
25
24

Comprehensive Analysis of Hypermutation in Human Cancer.
Brittany B Campbell, Nicholas Light, David Fabrizio, Matthew Zatzman, Fabio Fuligni, Richard de Borja, Scott Davidson, Melissa Edwards, Julia A Elvin, Karl P Hodel,[...]. Cell 2017
412
11

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, Seiji Sakata, Misako Matsumoto, Seiji Nagano, Takuya Maeda, Yasunobu Nagata, Akira Kitanaka, Seiya Mizuno,[...]. Nature 2016
389
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.